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COMPOSITION AND METHOD FOR THE 
PREVENTION AND TREATMENT OF 
OXIDATIVE DAMAGE IN OCULAR TISSUES 
GOVERNMENT RIGHTS 
This invention was made in part with government Support 
under grant number R01-10595 awarded by the National 
Eye Institute. The government has certain rights in the 
invention. 
BACKGROUND OF THE INVENTION 
In one aspect, the present invention relates generally to 
the field of ophthalmology and, more particularly, to com 
positions and methods for the prevention or treatment of eye 
diseases, Such as cataracts. In another aspect, the present 
invention relates to the prevention or treatment of diseases 
caused by oxidative StreSS or having oxidative StreSS as a 
component. 
The lens consists of concentric layers of fiber cells with 
hexagonal croSS Sections packed together to create a very 
regular array of fiber cells which stretch from anterior to 
posterior pole. The lens fiber cells lose all intracellular 
organelles that could contribute to light Scattering during the 
process of differentiation and the ctyoplasmic protein con 
centration increases markedly. Lens transparency is the 
result of a uniform Structure of the cells cytoplasm, which 
exists in an ordered, homogeneous State. 
Approximately 35% to 60% of the total mass of the lens 
consists of Structural proteins with the remainder being 
water. These cells contain primarily the crystallin proteins. 
When these proteins are modified by oxidative stress, con 
formational changes and aggregates result which, in turn, 
disrupt the protein lattice and damage the cell. This cellular 
damage leads to a further disruption of the regular layers of 
cells, resulting in opacities, or cataracts, of the lens. 
More than 90% of the total lens protein consists of alpha, 
beta, and gamma crystallins (in excess of 300 mg/ml) in the 
lens cell cytoplasm. Crystallins are proteins containing 
numerous Sulfhydryl groups, making them Susceptible to 
oxidative damage. Protein S-thiolation, the formation of 
mixed disulfides between non-protein thiols and protein 
Sulfhydryl groups in the lens, is an early event under 
oxidative damage (Lou et al., “The role of protein thiol 
mixed disulfides in cataractogenesis,” Exp. Eye ReS., Vol. 50, 
819–26 (1990)). Protein-glutathione (PSSG) and protein 
cysteine (PSSC) are the products of such protein modifica 
tion that have been implicated as a direct precursor of 
protein-protein disulfides (PSSP) in rat lenses cultured with 
HO. These changes ultimately lead to protein insolubility, 
loSS of transparency of the lens tissue, and cataract formation 
(Cui et al., “The effect and recovery of long term HO 
exposure on lens morphology and biochemistry,” Exp. Eye 
Res., vol. 57, 157-67 (1993)). 
In unstressed normal cells, the concentration of 
S-thiolated proteins is very low and the dethiolation rate, 
i.e., the breakdown of mixed disulfides by reduction of 
disulfide bonds, may be sufficient to maintain the fully 
reduced protein Status. Such a Situation has been observed in 
the HO pre-exposed lenses after the oxidant was removed 
from the culture medium (Cui et al., Exp. Eye Res., vol. 57, 
157-67 (1993); Lou et al., “Further studies on the dynamic 
changes of glutathione and protein-thiol mixed disulfides in 
H2O induced cataract in rat lenses: distributions and effect 
of aging,” Curr. Eye Res., vol. 14, 951-58 (1995)). This 
implies that the maintenance of the redox Status of the 
Sulfhydryl groups of the protein is vital to the physiological 
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function of the lens, a tissue abundant in Sulfhydryl groups 
and extremely Vulnerable to oxidative damage. 
The redox state of the cell is maintained by many 
reductants, such as glutathione (GSH), NADPH, ascorbate, 
and tocopherol (Spector, “The lens and oxidative stress,” in 
Oxidative Stress, Oxidants, and Antioxidants (Sies, Ed.) pp. 
529-58, Academic Press: London (1991)). Among these 
reductants, GSH has a significant role in maintaining the 
reduced condition of the cell. Traditionally, GSH with 
glutathione reductase has been viewed as the System respon 
Sible for maintaining and regenerating the protein thiol 
groups that are Susceptible to oxidation. Reduced GSH and 
other thiol containing molecules act, at least indirectly, as 
oxygen free radical Scavengers, due to their easily oxidizable 
Sulfhydryl groups and hence act as Sulfhydryl antioxidants in 
normal lenses. Glutathione reductase regenerates GSH from 
its disulfide oxidized form (GSSG) and acts as a sulfhydryl 
buffering System, continually controlling the Sulfhydryl/ 
disulfide balance in the cell. GSH exists in great excess of 
its GSSG oxidized counterpart in the cellular cytoplasm, 
thus creating a Strong potential for cytosolic proteins to exist 
in a Sulfhydryl-reduced, non-crosslinked State. Deficiencies 
of GSH have been observed in cataractous lenses (Biochim 
et Biophy's Acta, vol. 1138, 11-19 (1992)). This deficiency 
leads to a reduced ability of the cell to repair damage 
asSociated with oxidative StreSS. 
Antioxidant therapy has been proposed to ameliorate the 
destructive effects of oxidation resulting in the formation of 
cataracts (American J. of Clinical Nutrition, vol. 53, 
pp.335S-345S (1991) and pp.352S-355S (1991)). Such 
proposed therapy has included the Systemic administration 
of vitamins C and E and beta carotene. The use of phenolic 
antioxidants, Such as probucol, to inhibit the development of 
cataracts, is disclosed in U.S. Pat. No. 5,061,734 to Mao et 
al. The use of N,N'-bis(mercaptoacetyl)hydrazine deriva 
tives as anticataract agents is disclosed in U.S. Pat. Nos. 
5,686,450 and 5,688,828, both to Hellberg et al. PCT 
Application No. WO 94/03167 discloses the use of N-(3- 
mercapto-2,2-dimethylpropanoyl)cysteine and the intramo 
lecular disulfide thereof for the treatment of cataract. Alpha 
lipoic acid is disclosed as an anticataract agent in Maitra et 
al., “Alpha-Lipoic Acid Prevents Buthionine Sulfoximine 
Induced Cataract Formation in Newborn Rats.” Free Radi 
cal Biology and Medicine, vol. 18, pp. 823–829 (1995). The 
use of phase Separation inhibitorS is proposed in U.S. Pat. 
No. 5,401,880 to Clark et al. 
Cataracts are the leading cause of blindness in humans, 
with more than one million cataract extractions performed 
each year in the United States and with an estimated 5 to 10 
million people becoming visually disabled each year due to 
cataracts. Cataracts in animals also pose a Significant vet 
erinary problem. Currently, no accepted nonSurgical therapy 
for the prevention and treatment of cataracts exists. 
Although various drugs have been proposed for use in the 
treatment and prevention of cataracts, it would be desirable 
to avoid potential adverse effects, Such as chemical related 
toxicity, of Such compounds. 
SUMMARY OF THE INVENTION 
The present invention is directed to compositions and 
methods for preventing or delaying the onset of cataracts 
and for treating or inhibiting the progression of cataracts in 
animals through the administration of thioltransferase 
(glutaredoxin) or derivatives thereof. In another aspect, the 
present invention is directed to the prevention and treatment 
of oxidative StreSS or damage and disease States associated 
US 6,379,664 B1 
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therewith through the administration of thioltransferase or 
derivatives thereof. In one embodiment the animal may be 
a mammal. When the animal is a mammal, it may be a 
human. 
The present invention is based on our discovery of the 
presence of thioltransferase in the lens and other ocular 
tissues, including the cornea cells, iris, and retina, all Vul 
nerable to oxidative damage. Thioltransferase has been 
found by us to be an intrinsic repair System capable of 
dethiolating mixed disulfides associated with cataract ini 
tiation and formation, and thus is capable of repairing 
damaged proteins and nonprotein thiols by restoring them to 
their respective normally reduced States. It has also been 
found by us that thioltransferase can dethiolate enzymes 
damaged by thiolation, thus reactivating the catalytic func 
tion of the enzymes. Because thioltransferase in an endog 
enous biomolecule, it will cause no adverse effects due to 
chemical related toxicity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The detailed description of the invention may be best 
understood when read in reference to the accompanying 
drawings wherein: 
FIG. 1 shows the nucleotide and the deduced amino acid 
Sequence of the coding region of the human lens thioltrans 
ferase, 
FIG. 2 shows the alignment of the deduced amino acid 
Sequence of thioltransferases, 
FIGS. 3A and 3B show the time dependent dethiolation in 
the presence and absence of HLTT; 
FIG. 4 shows the detoxification of bolus HO (0.5 mM) 
by rabbit lens epithelial cell line N/N 1003A. 
FIG. 5 shows the effect of bolus HO to lens GSH and 
protein-thiol mixed disulfide in N/N 1003A cells; 
FIG. 6 shows the effect of bolus HO (0.5 mM) on 
enzyme activities in N/N1003A cells; 
FIG. 7 shows thioltransferase activity in lens epithelial 
cells (N/N 1003A) treated with various levels of H.O. 
FIG. 8 shows the effect of HO on the growth of rabbit 
lens epithelial cells, 
FIG. 9 shows the regeneration of G3PD from HO (0.5 
mM) pretreated rabbit cells by recombinant human lens 
thioltransferase; and 
FIG. 10 shows the time dependency of regeneration of 
G3PD from HO pretreated rabbit cells by purified recom 
binant human lens thioltransferase. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Thioltransferase acts as a repair enzyme under oxidative 
StreSS to prevent lens protein aggregation by protecting thiol 
groups from oxidation and restoring thiolated proteins to 
their normal reduced State by cleaving protein-thiol mixed 
disulfides, thus preventing protein-protein disulfide 
crosslinking. Thioltransferase also acts as a primary anti 
oxidant by protecting the lens from oxidation by its ability 
to regenerate ascorbic acid, an important free radical Scav 
enger. 
In a first aspect, the present invention provides a method 
of inhibiting the formation of a cataract in an eye of a 
Subject, which comprises administering to the Subject a 
pharmaceutical composition comprising an effective cata 
ract inhibiting amount of a thioltransferase or thioltrans 
ferase derivative. The pharmaceutical composition prefer 
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ably further comprises a pharmaceutically acceptable carrier 
in accordance with formulation techniques known to those 
skilled in the art. 
AS used herein, the term “pharmaceutically acceptable 
carrier encompasses any of the Standard pharmaceutically 
acceptable carriers known to those skilled in the art. 
Examples of Such Standard carriers include, but are not 
limited to, phosphate buffered saline (PBS) solution, water, 
emulsions Such as water/oil emulsions or a triglyceride 
emulsion, various types of wetting agents, tablets, enteric 
coated tablets and capsules, and So forth. 
The thioltransferase may be any naturally occurring 
thioltransferase, including, but not limited to mammalian 
derived thioltransferases. Exemplary mammalian thioltrans 
ferases include, but are not limited to, human, pig, cow, and 
rabbit thioltransferases. Also contemplated are tissue spe 
cific variants, Such as liver, RBC, placental, and ocular 
thioltransferases, and So forth. Other thioltransferases are 
also contemplated, Such as thioltransferase derived from E. 
coli. In a preferred embodiment, the thioltransferase is 
human lens thioltransferase as defined by SEQ ID NO:1. 
In the above described methods of inhibiting the forma 
tion of cataracts in an eye, the eye may already contain one 
or more developing or fully developed cataracts before it is 
contacted with the thioltransferase or derivative thereof. 
Accordingly, the above disclosed method can be used to 
inhibit the formation of further cataracts in the eye, to inhibit 
the progression of any developing cataracts already present 
in the eye, or to at least partially reverse the development of 
Such mature or developing cataracts in the eye. 
Alternatively, the eye may be free of any developing or fully 
developed cataracts when it is contacted with the thioltrans 
ferase or derivative thereof. 
Any Suitable means known to those skilled in the art may 
be used to administer the pharmaceutical composition to the 
Subject in accordance with the present invention. The com 
position may be administered Systemically, or, in a preferred 
embodiment, is administered to the eye by directly applying 
the composition to the eye. 
In another aspect, the present invention provides pharma 
ceutical compositions comprising the thioltransferase or 
derivatives thereof according to the present invention. Any 
Suitable means may be used to administer the pharmaceu 
tical compositions to a Subject in accordance with the 
present invention. Formulations for the thioltransferase or 
derivatives thereof according to the present invention may 
be any conventional formulation for protein or peptide 
drugs, Such as found in Remington's Pharmaceutical 
Sciences, latest edition (Mack Publishing Co.: Easton, Pa.). 
Typically, proteins and peptides are administered by 
injection, Such as intravenous, intramuscular, Subcutaneous, 
or intraperitoneal injection, or using formulations for trans 
mucosal or transdermal delivery. These formulations gener 
ally include a detergent or penetrant Such as bile Salts, 
fusidic acids, and the like. The pharmaceutical composition 
may be injected into any part of the Subject's body, including 
into one or both of the subject's eyes. These formulations 
may also be administered as aerosols or Suppositories. In the 
case of transdermal administration, the formulation may be 
in the form of a topical ointment, lotion, cream or skin patch, 
and may include a transdermal agent. For Systemic 
application, the pharmaceutical composition may be applied 
to any part of the Subject's body. The compositions accord 
ing to the present invention may be adapted for oral 
administration, i.e., in the form of tablets, capsules, 
Solutions, Suspensions, and other dosage forms adapted for 
US 6,379,664 B1 
S 
oral administration, provided the formulation protects the 
thioltransferase or derivatives thereof according to the 
present invention from degradation in the digestive System. 
Optimization of dosage regimen and formulation is con 
ducted as a routine matter and as generally performed in the 
art. Although thioltransferase is generally a heat Stable 
enzyme, it should be Stored at a cold temperature. 
In a preferred embodiment, the eye is contacted directly 
with the thioltransferase or derivative thereof. Any suitable 
means known to those skilled in the art may be used to 
contact the eye with the thioltransferase or derivative 
thereof. Examples of Such methods include, but are not 
limited to, injection into the eye, or, dropping, Spraying, or 
other topical application to the eye. Vehicles for topical 
ophthalmic formulations are generally known to those 
skilled in the art. Various electrolytes, Solvents, co-Solvents, 
Surfactants, preservatives or antimicrobial agents, Viscosity 
building agents, etc., are taught in U.S. Pat. No. 5,686,450, 
incorporated herein by reference in its entirety. 
AS used herein, the term “effective cataract-inhibiting 
amount' is intended to encompass any amount which will 
inhibit the progression or formation of cataracts in an eye. 
The route of administration and the dosage regimen will be 
determined by skilled clinicians. AS Such, the effective 
cataract-inhibiting amount of the compound will depend on 
various factors known to those skilled in the art, which 
include, but are not limited to, the size of the eye, the exact 
nature and Severity of the condition being treated Such as the 
number and progression of any mature or developing cata 
racts already present invention eye, whether the eye is to be 
contacted a single time or periodically over a period of time 
and the length of such period of time. The period of time 
may be any number of days, weeks, months, or years. In one 
embodiment, the thioltransferase or derivative thereof is 
administered from one to four times per day until the desired 
results have been achieved. In one embodiment, the effective 
cataract-inhibiting amount of the thioltransferase or deriva 
tive thereof is an amount that provides a given level of 
enzyme activity in the lens. A typical lens (old lens, i.e., 65 
years or older) weighs about 200 mg and about 30% of the 
weight are proteins. The enzyme activity in a typical old 
human lens is about 50.6 m Unit or about 1.2x10 Unit 
activity per mg lens protein. 
For direct administration to the eye, the dosage may be an 
amount which provides an enzyme activity of about 1.2x 
10 Unit activity per mg lens protein or higher. In another 
embodiment, the dosage may be an amount that provides an 
activity of one to Several, or more, orders of magnitude 
higher than 1.2x10 Unit activity per mg lens protein. In 
one embodiment, the dosage may be an amount that pro 
vides an activity of about 1.2 Unit activity per mg lens 
protein or higher. In another embodiment, the dosage may be 
an amount that provides an activity of about 1.2x10 Unit 
activity per mg lens protein or higher. 
For Systemic administration, the dosage is an amount that 
provides an activity of 1.2x10 Unit activity per mg lens 
protein or higher. In another embodiment, the dosage may be 
an amount that provides an activity of one to Several, or 
more orders of magnitude higher than 1.2x10 Unit activity 
per mg lens protein. In one embodiment, the dosage may be 
an amount that provides an activity of about 1.2 Unit activity 
per mg lens protein or higher. In another embodiment, the 
dosage may be an amount that provides an activity of about 
1.2x10 Unit activity per mg lens protein or higher. It will 
be understood that to achieve the desired level of activity in 
the lens, a dose administered Systemically will generally be 
higher than a dose administered directly to the eye. 
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In another embodiment, the administration of thioltrans 
ferase or a derivative thereof may comprise Surgically 
removing the lens of the eye from the Subject, applying the 
thioltransferase or derivative thereof to the lens, and then 
Surgically replacing the lens. 
In one embodiment of the above described method, the 
Subject is a mammal. When the Subject is a mammal, the 
Subject may be a human being. 
This invention further provides treatment, prevention, or 
inhibiting the progression of other eye diseases, including, 
but not limited to, glaucoma, macular degeneration, uveitis, 
iritis, cornea inflammation (either by injury or disease) or 
other trauma to the eye. Also, this invention further provides 
a method of treating, preventing, or inhibiting the progres 
Sion of a disease, in a Subject, resulting from oxidative StreSS 
which comprises administering to the Subject a pharmaceu 
tical composition comprising an effective oxidative StreSS 
inhibiting amount of thioltransferase or derivative thereof. 
AS used herein, a disease resulting from oxidative StreSS is 
any disease resulting from the effects of reactive oxygen 
Species generated in cells. Reactive oxygen Species include 
Superoxide (O.), H2O, hydroxyl (OH.) radicals, and Sin 
glet oxygen (O.). Reactive oxygen species may be generated 
in cells during aerobic cellular metabolism. For example, O. 
is converted to Superoxide by oxidative enzymes in the 
endoplasmic reticulum, mitochondria, plasma membrane, 
peroxisomes, ctyosol, and So forth. Superoxide is converted 
to H2O by dismutation and thence to hydroxyl by the 
Fe"/Cu" catalyzed Fenton reaction or through the Haber 
Weiss reaction. HO is also derived directly from oxidases 
in peroxisomes. Reactive oxygen Species may also be ini 
tiated within cells by absorption of radiant energy Such as 
X-rays, ultraViolet light, or other ionizing radiation. Reactive 
oxygen Species may also be produced by reaction of other 
free radicals, metabolism of chemicals, drugs, chemothera 
puetic agents, pesticides, cigarette Smoke, and fatty foods. 
Diseases which may result from oxidative StreSS are 
generally known to those skilled in the art, and include, but 
are not limited to, rheumatoid arthritis, lupus, Sickle cell 
anemia, Sickle cell disease, the effects of aging, lipid per 
oxidation of membranes, glycosylation of proteins, oxida 
tive modification of proteins, including Sulfhydryl mediated 
croSS linking, fragmentation of polypeptide chains, and 
enzyme degradation. Oxidative StreSS causes oxidation of 
DNA and damages DNA in cells. Such damage may lead to 
the formation of tumors. Thus, diseases which result from 
oxidative StreSS include diseases which comprise the forma 
tion of tumors resulting from oxidative StreSS. Diseases 
which comprise the formation of tumors include cancer. For 
example, reactions with thymine in DNA produce Single 
stranded breaks in DNA. Such DNA damage has been 
implicated not only in cell death, but also, in eventual 
malignant transformation of cells. Mitochondrial DNA is 
also affected by oxidative StreSS. 
Other diseases which may result from oxidative stress 
include diseases coronary and/or circulatory System, dis 
eases of the central nervous system (CNS), inflammatory 
diseases, diseases of the pulmonary System, protein conden 
sation diseases, and other diseases. Such diseases include 
myocardial infarction, Stroke, angina, atherosclerosis, 
ischemic disease, reperfusion injury, hypercholsterolemia, 
adhesion formation, glaucoma, idiopathic pulmonary 
fibrosis, chronic renal failure, nephrolithiasis, 
nephrosclerosis, gastric ulcer, cholesterol gallstone disease, 
hepatitis, epilepsy and Parkinson's disease, Alzheimer's 
disease, asthma, psoriasis, multiple myeloma, and Side 
effects of drugs. Such as anticancer drugs, Side effects of 
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radiation, and so forth. Thioltransferase or derivatives 
thereof may also be for the treatment of diabetes and 
complications thereof Such as diabetic cataract, diabetic 
retinopathy, neuropathy, nephropathy, and neovasculariza 
tion of the cornea or retina. 
The compositions comprising thioltransferase or deriva 
tives thereof preferably further comprise one or more phar 
maceutically acceptable carriers as described above which 
includes, but is not limited to, PBS, water, emulsions Such 
as oil/water emulsions or triglyceride emulsions, various 
types of wetting agents, oral formulations, and So forth. A 
pharmaceutically acceptable carrier may be selected taking 
into account the desired mode of administration. 
Any Suitable means known to those skilled in the art may 
be used to administer the pharmaceutical composition to the 
Subject in accordance with the present invention. The com 
position may be administered Systemically, or, in a preferred 
embodiment, is administered to the location of oxidative 
StreSS. 
In another aspect, the present invention provides pharma 
ceutical compositions comprising the thioltransferase or 
derivatives thereof according to the present invention. Any 
Suitable means may be used to administer the pharmaceu 
tical compositions to a Subject in accordance with the 
present invention. Formulations for the thioltransferase or 
derivatives thereof according to the present invention may 
be any conventional formulation for protein or peptide 
drugs, such as found in Remington's Pharmaceutical Sci 
ences (Mack Publishing Co.: Easton, Pa.). Proteins and 
peptides may advantageously be administered by injection, 
Such as intravenous, intramuscular, Subcutaneous, or intra 
peritoneal injection, or using formulations for transmucosal 
or transdermal delivery. These formulations generally 
include a detergent or penetrant Such as bile Salts, fusidic 
acids, and the like. The pharmaceutical composition may be 
injected into any part of the Subject's body, including one or 
both of the subject's eyes. These formulations may also be 
administered as aerosols or Suppositories. In the case of 
transdermal administration, the formulation may be in the 
form of a topical ointment, lotion, cream or skin patch, and 
may include a transdermal agent. For Systemic application, 
the pharmaceutical composition may be applied to any part 
of the Subject's body. The compositions according to the 
present invention maybe adapted for oral administration, 
i.e., in the form of tablets, capsules, Solutions, Suspensions, 
and other dosage forms adapted for oral administration, 
provided the formulation protects the thioltransferase or 
derivatives thereof according to the present invention from 
degradation in the digestive System. Optimization of dosage 
regimen and formulation is conducted as a routine matter 
and as generally performed in the art. Although thioltrans 
ferase is generally a heat Stable enzyme, it should be Stored 
at a cold temperature. 
In the above described method of treating or preventing a 
disease resulting from oxidative StreSS, any Suitable means 
known to those skilled in the art may be used to administer 
the thioltransferase or derivative thereof to the subject. In 
one embodiment a pharmaceutical composition comprising 
thioltransferase or a derivative thereof is administered topi 
cally to a part of the subject's body where oxidative stress 
is expected to occur, is likely to occur, or may occur. In 
another embodiment, a pharmaceutical composition com 
prising thioltransferase or a derivative thereof is adminis 
tered topically to a part of the Subject's body where oxida 
tive StreSS has occurred. It will be recognized, however, that 
topical application to one part of a Subject's body can be 
expected to have beneficial Systemic effects on other parts. 
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Where topical application is used, the composition may be 
in the form of a cream or lotion and may include a trans 
dermal agent. 
In yet another embodiment, a pharmaceutical composition 
comprising thioltransferase or a derivative thereof is orally 
administered to the Subject. If oral administration is 
employed, the composition may be in the form of a capsule, 
tablet, Suspension, Solution, and So forth. 
When treating any of the above mentioned eye disorders, 
an ophthalmic formulation as detailed above may advanta 
geously be employed. 
In another embodiment, a pharmaceutical composition 
comprising thioltransferase or a derivative thereof may be 
injected into the Subject. Injection may be intramuscular, 
intraperitoneal, intravenous, or Subcutaneous. The pharma 
ceutical composition may be injected into any part of the 
Subject's body, including the part of the body where oxida 
tive StreSS has occurred or is expected to occur, is likely to 
Occur, or may occur. 
AS used herein, an “effective oxidative StreSS inhibiting 
amount' is intended to encompass an amount of thioltrans 
ferase or derivative thereof which will inhibit the generation 
of reactive oxygen Species in cells. The route of adminis 
tration and the dosage regimen will be determined by skilled 
clinicians. AS Such, the effective oxidative StreSS inhibiting 
amount will depend on various factors known to those 
skilled in the art. Such factors include, but are not limited to, 
the size of the Subject, the mode of administration, the exact 
nature and Severity of the condition being treated, whether 
the thioltransferase or derivative thereof is to be adminis 
tered a single time or periodically over a period of time and 
the length of such period of time. The period of time may be 
any number of days, weeks, months, or years. In one 
embodiment, the thioltransferase or derivative thereof is 
administered from one to four times per day until the desired 
results have been achieved. In one embodiment, the effective 
oxidative StreSS inhibiting amount of the thioltransferase or 
derivative thereof is an amount that provides a given level of 
enzyme activity in the affected area. 
For direct administration of the compositions according to 
the present invention to the affected area, the dosage may be 
an amount Sufficient to provide a normal physiological level 
of activity or higher. In another embodiment, the dosage is 
an amount which provides an activity level which is from 
one to Several, or more, orders of magnitude higher than the 
normal physiological level of activity. In Still another 
embodiment, the dosage is an amount which provides an 
activity level which is three or more orders of magnitude 
higher than the normal physiological level of activity. In 
another embodiment, the dosage is an amount which pro 
vides an activity level which is six or more orders of 
magnitude higher than the normal physiological level of 
activity. In yet another embodiment, the dosage is an amount 
which provides an activity of about 1.2x10 Unit activity 
per mg protein in the affected area or higher. In another 
embodiment, the dosage may be an amount that provides an 
activity of one to Several, or more, orders of magnitude 
higher than about 1.2x10 Unit activity per mg protein. In 
one embodiment, the dosage may be an amount that pro 
vides an activity of about 1.2 Unit activity per mg protein or 
higher. In Still another embodiment, the dosage may be an 
amount that provides an activity of about 1.2x10 Unit 
activity per mg protein or higher. 
For Systemic administration, the dosage may be an 
amount Sufficient to provide a normal physiological level of 
activity or higher in the affected area. In another 
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embodiment, the dosage is an amount which provides an 
activity level which is one to Several, or more, orders of 
magnitude higher than the normal physiological level of 
activity. In another embodiment, the dosage is an amount 
which provides an activity level which is three or more 
orders of magnitude higher than the normal physiological 
level of activity. In another embodiment, the dosage is an 
amount which provides an activity level which is six or more 
orders of magnitude higher than the normal physiological 
level of activity. In another embodiment, the dosage is an 
amount which provides an activity of about 1.2x10 Unit 
activity per mg protein in the affected area or higher. In 
another embodiment, the dosage may be an amount that 
provides an activity of one to Several, or more, orders of 
magnitude higher than 1.2x10 Unit activity per mg pro 
tein. In one embodiment, the dosage may be an amount that 
provides an activity of about 1.2 Unit activity per mg protein 
or higher. In another embodiment, the dosage may be an 
amount that provides an activity of about 1.2x10 Unit 
activity per mg protein or higher. It will be understood that 
to achieve the desired level of activity in the affected area, 
a dose administered Systemically will generally be higher 
than a dose administered directly to the affected area. For 
treatment of the eye disease other than cataracts, the dosages 
and regimens, formulation, and administration methods 
employed may generally be comparable to those detailed 
above for treatment of cataracts. 
In one embodiment of the above described method of 
preventing or inhibiting the progression of a disease caused 
by oxidative stress, the subject maybe a mammal. When the 
Subject is a mammal, the Subject may be a human being. 
In one embodiment according to the present invention, the 
thioltransferase is human lens thioltransferase (HLTT). 
When the thioltransferase is HLTT, the HLTT may be 
recombinant human thioltransferase (RHLT) according to 
the amino acid sequence set forth in SEQ ID NO:2. 
In an alternative embodiment, the thioltransferase may be 
another thioltransferase as described above, including, but 
not limited to, the thioltransferases depicted in SEQ ID 
NOS:3-7. 
In another embodiment, the thioltransferase may be any 
isomer or isoenzyme (isozyme) of HLTT or any isomer or 
isozyme of thioltransferase from other organisms, including 
tissue Specific thioltransferases. Tissue Specific thioltrans 
ferases include, but are not limited to, thioltransferases from 
ocular tissues, RBC, liver, placenta, and So forth. 
In another embodiment, the thioltransferase may be a 
thioltransferase derivative. Proteins useful as thioltrans 
ferase derivatives include proteins or polypeptides having an 
amino acid Sequence Substantially homologous to at least a 
portion of the amino acid Sequence Set forth in any of amino 
acid sequences set forth in SEQ ID NOS:2-7, preferably 
SEQ ID NO:2. The term “homologous” refers to the one to 
one correlation between the Sequences of two polypeptides. 
It will be recognized by those skilled in the art that 100% 
homology is not required in all cases and the present 
invention is intended to encompass thioltransferase deriva 
tives which are Substantially homologous to human lens 
thioltransferase or other thioltransferases. Substantial 
homology requires only that the essential nature of the 
polypeptide, i.e., folding characteristics and unique features 
Such as the active site or other critical regions are preserved. 
Thus, modifications of thioltransferase are anticipated and 
are within the Scope of the present invention. Such modifi 
cations may be deliberate, as through Site directed 
mutagenesis, or may be accidental as through mutations in 
hosts which are producers of the thioltransferase. 
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In Some embodiments of the present invention, the thiol 
transferase derivatives may be at least about 75% homolo 
gous to the Sequence of a known wild type or native 
thioltransferase, including those set forth in SEQ ID 
NOS:3-7, or in a preferred embodiment, may be at least 
about 75% homologous to the sequence of native HITT set 
forth in SEQ ID NO:2. In other embodiments of the present 
invention, the thioltransferase derivatives may be at least 
about 85% homologous to the Sequence of a known native 
thioltransferase, including those set forth in SEQ ID 
NOS:3-7, or in a preferred embodiment, may be at least 
about 85% homologous to the sequence of native HITT set 
forth in SEQ ID NO:2. In yet other embodiments of the 
present invention, the thioltransferase derivatives may be at 
least about 95% homologous to the sequence of a known 
native thioltransferase, including those set forth in SEQ ID 
NOS:3-7, or in a preferred embodiment, may be at least 
about 95% homologous to the sequence of native HITT set 
forth in SEQ ID NO:2. It is also anticipated that certain 
non-commonly occurring amino acids may be Substituted 
for commonly occurring counterparts to confer desirable 
characteristics to the resulting polypeptide. 
Furthermore, it is contemplated in Some aspects of the 
present invention that thioltransferase derivatives may 
encompass polypeptides that comprise only a portion of the 
Sequence of thioltransferase, Such as known thioltrans 
ferases including those listed in SEQ ID NOS:3-7 and, in a 
preferred embodiment, thioltransferase derivatives may 
encompass polypeptides that comprise only a portion of the 
sequence of HLTT set forth in SEQ ID NO:2. This may be 
the case, for example, for a chimeric protein encompassing 
active or otherwise desirable portions of a number of pro 
teins. A portion may also refer to a truncated polypeptide, be 
it Substantially truncated or only slightly truncated. Such 
truncated polypeptides may be the result of an idiosyncracy 
in the mode of production which results in truncation of 
amino acids from a terminal end, or a finding that the 
truncated polypeptide has activity similar to or better than 
the full-length protein. Preferably, such truncations should 
not remove regions critical for biological activity. In a 
preferred embodiment, Such truncated polypeptides may 
include, for example, truncated proteins containing the three 
highly conserved regions as set forth in FIG. 2. It is 
contemplated that there may be other critical regions as well, 
e.g., regions necessary for inducing proper folding and 
proper three-dimensional conformation, catalytic activity, 
and the like. The ascertainment of noncritical regions is 
readily accomplished by deleting or modifying candidate 
regions and conducting an appropriate assay for thioltrans 
ferase activity. Regions where modifications result in a loSS 
of activity are critical; regions wherein the alteration results 
in the same or Similar activity are considered noncritical. 
Of course, in Still other aspects of the present invention, 
the full length protein, as set forth in SEQ ID NO:2, is 
contemplated. 
The thioltransferase or derivative thereof according to the 
present invention, depending on the pH of its environment, 
if Suspended or in Solution, or of its environment when 
crystallized or precipitated, if in Solid form, may be in the 
form of pharmaceutically acceptable Salts or may be in 
neutral form. The free amino groups of the protein are, of 
course, capable of forming acid addition Salts with, for 
example, inorganic acids, Such as, for example, 
hydrochloric, phosphoric, or Sulfuric acid, or with organic 
acids Such as, for example, acetic, glycolic, Succinic, man 
delic acid, and So forth. The free carboxyl groups are capable 
of forming Salts with bases, including inorganic baseS Such 
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as Sodium, potassium, or calcium hydroxides, and organic 
bases, Such as piperidine, glucosamine, trimethylamine, 
choline, and caffeine. In addition, the protein may be modi 
fied by combination with other biological materials, Such as 
lipids and Saccharides, or by Side chain modifications, Such 
as acetylation of amino groups, phosphorylation of hydroxy 
Side chains, or oxidation of Sulfhydryl groups. 
The thioltransferase or derivatives thereof according to 
the present invention are preferably purified and isolated. AS 
used herein, “purified” and "isolated” are intended to refer 
to molecules which have been purified or Synthesized So as 
to be Substantially homogeneous. It will be recognized that 
the terms do not exclude the possibility that certain impu 
rities may be present in the composition So long as the 
essential nature of the protein is intact. 
In another aspect, the present invention pertains to a DNA 
sequence which encodes HLTT, which includes a DNA 
Segment that can express the gene encoding HLTT, com 
prising the nucleotide sequence of SEQ ID NO:1. Also 
contemplated is a DNA sequence which comprises a DNA 
Segment analogous to the nucleotide Sequence of SEQ ID 
NO:1 wherein analogous DNA segment differs from the 
nucleotide sequence of SEQ ID NO:1 wherein one or more 
bases are replaced by other bases by means of the degen 
eracy of the genetic code without altering the corresponding 
amino acid Sequence. Contemplated in yet another embodi 
ment are DNA sequences which hybridize with the nucle 
otide sequence of SEQ ID NO:1 or a fragment thereof, 
wherein Said DNA segment encodes a polypeptide having 
thioltransferase activity. In still another embodiment, a DNA 
Segment encoding thioltransferase derivatives as defined 
above, including homologous amino acid Sequences and 
truncated amino acid Sequences. 
The present invention also provides a recombinant vector 
comprising the above mentioned DNA sequences. In another 
embodiment, the present invention provides an expression 
vector comprising the above mentioned DNA sequences. AS 
is well known, expression Systems are now available com 
patible with a wide variety of hosts, including procaryotic 
hosts Such as bacteria and eucaryotic hosts Such as yeast, 
plant cells, insect cells, mammalian cells, avian cells, and 
the like. In Still another embodiment, the present invention 
provides transformed cells obtained by introducing into a 
host cell a replicable recombinant DNA which comprises a 
self-replicable vector and a DNA sequence as set forth in 
SEQ ID NO:1 or other DNA sequence as described above. 
Transformed host cells may be any host cell which has been 
altered to contain an expression System according to the 
present invention by any convenient manner of introducing 
it, including transfection, Viral infection, electroporation, 
and so forth. In a preferred embodiment, the host cell is E. 
coli. 
The present invention also provides a proceSS for produc 
ing a recombinant HLTT (RHLT), which comprises cultur 
ing the above described transformant to produce RHLT and 
collecting the RHLT from the resultant culture. Any con 
ventional means for recovery of the protein may be 
employed. For example, the protein produced may be recov 
ered from the lysate of the cells if produced intracellularly, 
or from the medium if Secreted. Techniques for recovering 
recombinant proteins from cell cultures are well understood 
in the art, and the proteins can be purified using known 
techniques Such as chromatography, gel electrophoresis, 
Selective precipitation, and the like. 
Human lens thioltransferase can be prepared according to 
the method disclosed in Raghavachari et al., “Cloning, 
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high-level expression, and characterization of human lens 
thioltransferase,” Exp. Eye Res., vol. 66, pp. 465–475 
(1998), herein incorporated by reference in its entirety. Also 
incorporated by reference in its entirety is Lou et al., 
“Thioltransferase is present in the lens epithelial cells as a 
highly oxidative StreSS-resistant enzyme, Exp. Eye Res., 
vol. 66, pp. 476-486 (1988). Various examples will be 
described below. Such examples Serve to explain the prin 
ciples of the invention and are not restrictive of the invention 
as claimed. 
Materials 
The following materials were used in the cloning, expres 
Sion and characterization of human lens thioltransferase. 
pCR 3.1-Uri vector was purchased from Invitrogen. Primers 
for PCR amplification were custom made at Gibco-BRL. 
Expression vector pET-23a and its host cell BL2I (DE3) 
were obtained from Novagen Inc. T4 Poly nucleotide kinase, 
T4 DNA ligase, Taq DNA polymerase restriction enzymes, 
and random primer labeling kit were purchased from Gibco 
BRL. Reagents for electrophoresis and immunoblots were 
purchased from Bio-Rad. Protein assay reagent was pur 
chased from Pierce. 
Construction of Human Lens cDNA Library 
One hundred human lens capsulotomy Specimens were 
obtained from Dr. Joseph Horwitz, Jules Stein Eye Institute, 
UCLA. Total RNA was extracted and mRNA was purified 
on an oligo dT column. The mRNAs were converted into 
cDNAS and the double stranded cDNAS were subcloned into 
Uni-ZapTMXR vector using ZAP-cDNA synthesis Kit 
(Stratagene, La Jolla, Calif., U.S.A.) using EcoR1 and XhoI 
1 sites as described in the manual of the provider. The library 
was found to have 4x10" plaque forming units per ug 
original cl)NA. The background of the library was less than 
2%. Two microliters of the library was diluted (1:10) and 
used as the template for the PCR as described below. 
Production of an Initial cDNA Clone by PCR 
A21mer Sense (agcatggctcaagcatttgtg, SEQID NO:8) and 
a 24mer antisense (gaagaaaaatctgttttgtccccc, SEQ ID NO:9) 
primers were designed based on the known nucleotide 
sequence of pig liver thioltransferase (M31453 GenBank). 
The sense primer is phosphorylated by T4 Poly nucleotide 
kinase prior to amplification. This phosphorylated primer 
was used with the unphosphorylated antisense primer to 
generate a 520 bp PCR product phosphorylated on the 5' end 
using the template human lens cDNA library and Taq DNA 
polymerase. The conditions of the PCR in a reaction volume 
of 50 uL were as follows: 40 cycles at 94° C. for 1 min., 57 
C. for 1.5 min. and 720° C. for 2 min. The PCR products 
were size fractionated on a 2% agarose gel and the band 
corresponding to 520 bp was separated and purified using 
Qiagen's Gel agarose purification Kit (Vogelstein et al., 
“Preparative and analytical purification of DNA from 
agarose,” Proc. Natl. Acad. Sci. U.S.A., vol. 76, 6.15-79 
(1979)). This purified PCR product was used for Subsequent 
cloning purposes. 
Cloning of Lens Thioltransferase into TA3.1 Uni 
Vector 
The purified PCR fragment was cloned downstream of 
CMV promoter into TA3.1-Uni using T4DNA ligase at 14 
C. for 16 hr and Invitrogen's Top 10F cells were transformed 
with the recombinant pCR 3.1 Uni vector based on the 
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method of Mead et al., “A universal method for the direct 
cloning of PCR amplified nucleic acid,” Bio/techno, vol. 9, 
pp.657-63 (1991)). The transformants were selected on LB 
plates with 50 lug/ml Kanamycin. The recombinant plasmid 
designated as PCR 3.1-HLTT were analyzed by restriction 
enzymes HindIII and EcoR1 for the presence of the insert. 
Nucleotide Sequence Analysis of the Recombinant 
Lens. Thioltransferase 
cDNA sequencing of the recombinant thioltransferase 
cDNA from both the 5' and 3’ directions were performed on 
automated fluorescence DNA sequencer using Thermose 
quenase (Amersham) at the Licor-Biotech Inc., Lincoln, 
Nebr., U.S.A. 
Sub Cloning into p.T 23a Vector 
PCR 3.1-HLTT was digested with Nhe 1 and EcoR1 at 37 
C. for 4 hr in React 4 buffer (Gibco). The HLTT cDNA 
fragment released after restriction enzyme digestion was 
Separated on 2% agarose gel, purified and cloned into the 
Nhe 1 and EcoR1 sites of p.T 23a expression vector driven 
by T7 promoter using T4 DNA ligase. BL21 (DE3) cells 
were transformed with peT23a-HLTT and the transformants 
were selected on LB plates with 50 tug/ml amplicillin. The 
resulting positive clones were designated as pET23a-HLTT. 
Expression of HLTT 
Transformed BL21 cells were cultured at 37° C. in LB 
medium with 50 tug/ml amplicillin until an ODoo of 0.4–0.6 
was reached. At this time isopropylthiogalactoside (IPTG) 
was added to a final concentration of 0.5 mM and the culture 
was continuously incubated for up to 8 hr at 37° C. Equal 
number of cells (~1 ml) were removed at various time 
intervals (0, 2, 4, 6, 8 hr) to monitor the rate of HLTT 
induction. 
Preparation of Crude Recombinant HLTT 
Cells were harvested after 0, 2, 4, 6, and 8 hr of IPTG 
induction by centrifugation at 3500 g for 20 minutes and the 
pellet was resuspended in 1 ml of 10 mM phosphate buffer 
pH 7.4 containing 1 mM dithiothreitol (DTT). 1 mM phenyl 
methylsulfonyl fluoride (PMSF), Lysozyme was added to a 
final concentration of 0.2 mg/ml with Stirring and the cells 
were disrupted by Sonication for 3 minutes at 30 second 
intervals. The lysed cells were centrifuged to remove the cell 
debris and the Supernatant was used for protein analysis, 
thioltransferase assay, and Western blot analysis. 
Protein Determination 
Protein content of the crude extract was determined by the 
BCA protein assay protocol according to Smith et al., 
“Measurement of protein using BCA.” Anal. Biochem., vol. 
150, 76–85 (1985), with bovine serum albumin as the 
Standard. 
Measurement of Thioltransferase Activity 
Thioltransferase activity was measured as described pre 
viously (Raghavachari et al., “Evidence for the presence of 
thioltransferase in the lens,” Exp. Eye Res., vol. 63, 433-41 
(1996)) with hydroxy ethyl disulfide (HEDS) as substrate. 
Briefly the reaction mixture contained 0.2 mM NADPH, 0.5 
mM GSH, 0.1 mM Phosphate buffer, 0.4 units GSSG 
reductase and an aliquot of the crude cell extract. The 
reaction was initiated by the addition of 2 mM HEDS at 
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room temperature and the decrease in absorbance at 340 nm 
was monitored in a Beckman spectrophotometer. A blank 
reaction without the enzyme was monitored simultaneously 
as a control blank. 
Measurement of Dehydroascorbate Reductase 
Activity 
Dehydroascorbate reductase activity was measured by the 
direct spectrophotometric method of Stahl et al., “A Spec 
trophotometric assay for dehydroascorbate reductase, Anal. 
Biochem., vol. 131, 341-44 (1983), based on the change in 
absorbance at 265.5 nm as dehydroascorbic acid is reduced 
to ascorbic acid. The reaction mixture contained 137 mM 
sodium phosphate buffer pH 6.8.1 mM EDTA, 2 mM GSH, 
1 mM DHA and various amounts of enzyme in a total 
volume of 500 ul. The reaction was initiated by the addition 
of DHA and the change in absorbance at 265 nm was 
monitored for 5 min. Ablank without any enzyme served as 
the control. 
Preparation of Protein Mixed Disulfides-PSSG 
and PSSC 
Purified BSA, alpha and gamma crystallins from bovine 
lens were conjugated to H-GSH and 'C-cystine to form the 
corresponding protein-thiol mixed disulfides PSSG and 
PSSC based on the procedure of Dickerson et al., “The 
culture of rat lenses in high Sugar media: effect on mixed 
disulfide levels,” Curr. Eye Res., vol.14, pp.109-18 (1994). 
In brief, to a 4 mg/ml of BSA, alpha and gamma crystallins 
were added 27.2 mg of 1 mci/ml H-GSH or 17.2 mg/ml 
"C-cystine and the samples were maintained at 20° C. for 
1 hr followed by a minimum of 18 hr at -20°C. The samples 
were then thawed and dialysed extensively to remove exceSS 
GSH, GSSG or cystine in 0.1 M potassium phosphate buffer 
pH 7 with 10 mM diethylene triamine penta acetic acid 
(DTPA). The purity of the synthesized protein-thiol mixed 
disulfides was verified on Superose 12 (gel filtration) col 
umn (Pharmacia) using Waters HPLC system. The incorpo 
ration of radioactivity in the mixed disulfide was determined 
simultaneously using the INUS B RAM system. The specific 
radioactivity of the synthesized BSA and crystallin-thiol 
mixed disulfides were found to be in the range of 0.25-0.7 
Ci/Mol protein. 
Dethiolation Assay with HLTT 
Dethiolation of H or 'C labeled protein-thiol mixed 
disulfides was carried out with purified human lens thiol 
transferase by a procedure similar to Mannervik et al., “Role 
of cytoplasmic thioltransferase in cellular regulation by 
thiol-disulphide interchange,” Biochem. J. vol. 190, pp. 
125-30 (1980). 
Initial specific radioactivities of all the radiolabeled Sub 
strates were within the range of 0.25-0.7 Ci/Mol protein. 
These substrates were incubated at 30° C. with 0.1 M 
potassium phosphate buffer pH 7.5, 2 units GSSG reductase, 
0.2 mM NADPH, 0.5 mM GSH in the absence or presence 
of HLTT. After preincubation at 30° C. for 5 min., reactions 
were started by the addition of radiolabeled PSSG or PSSC 
to a final concentration of 2 mM. Reactions were terminated 
at various times by the addition of 1 volume of ice cold 20% 
TCA followed by centrifugation for 10 min. An aliquot of 
the Supernatant was removed and added to 5 ml of bio-safe 
liquid Scintillation cocktail and counted in the liquid Scin 
tillation counter. Net release of radioactivity in the Super 
natant per ml of the reaction mixture was calculated. Thiol 
transferase activity is then expressed as mol of PSSG or 
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PSSC dethiolated per ug thioltransferase protein under the 
assay conditions mentioned above. 
SDS-PAGE and Immunoblotting Analysis 
The Laemmeli system (Laemmeli, “Cleavage of structural 
proteins during the assembly of the head of the bacterioph 
age T4,” Nature, vol. 277, pp. 680–88 (1970)) was 
employed for SDS-PAGE analysis. Immunoblotting analysis 
was performed as described previously (Blake et al., “A 
rapid Sensitive method for detection of alkaline phosphate 
conjugated antibody on Western blots,” Anal. Biochem., Vol. 
136, pp. 175-79 (1984)) in which polyclonal antiserum 
raised against PLTT was used as the primary antibody and 
alkaline phosphatase conjugated goat anti rabbit IgG color 
reaction System (Biorad) was used to detect the positive 
Signals. 
N-terminal Sequence Analysis 
An aliquot of the crude recombinant HLTT after induction 
with IPTG was separated on 15% SDS-PAGE. The gel was 
transferred to PVDF (poly vinylidene difluoride) membrane 
and stained with amido black. The heavily stained band after 
8 hr of IPTG induction corresponding to 11.5 KDa was 
sequenced on Procise-494sequencer at the Protein Core 
facility of University of Nebraska-Lincoln. 
Northern Blot Analysis 
Total RNA from bovine Lens, rabbit lens epithelial cells 
and pig liver were isolated and purified by the Single Step 
method of Chomczynski et al., “A Single Step method of 
RNA isolation by acid guanidium thiocyanate phenol 
chloroform extraction,” Anal. Biochem., vol. 162, 156-59 
(1987). Approximately 10 ug of the total RNA extracted 
from bovine lens, rabbit lens epithelial cells, pig liver, 
humanplacenta, and 5 lug of 0.24-9.5 kilobase pair RNA 
ladder (Gibco-BRL) were electrophoresed on an 11x14 cm 
agarose formaldehyde gel. The gel was rinsed in DEPC 
water several times, and RNA was transferred to a Nytran 
membrane (Schleicher and Sehuell) using the Turboblotter 
rapid downward transfer System. The membrane was pre 
hybridized and hybridized with human lens thioltransferase 
cDNA labeled with Pat 65° C. for 1 hr. The membrane was 
washed for 15 min at room temperature in 2XSSC solution, 
0.1% SDS twice. The final wash at high stringency was 
carried out at 60° C. for 15 min. The membrane was air dried 
and exposed to X-ray film for 2 days at -80 C. with 
intensifying Screens. To determine the integrity and equal 
loading of RNA, duplicate samples along with RNA markers 
were ran Simultaneously, Stained with ethidium bromide and 
photographed. 
Southern Blot Analysis 
DNA from rabbit lens epithelial cell line were extracted 
by the method of Gross-Bellard et al., “Isolation of high 
molecular weight DNA from mammalian cells,” Eur: J. 
Biochemistry, vol. 36, pp. 32–38 (1973). An aliquot of the 
genomic DNA was digested with EcoR1, HindIII, Pvull, 
Sac1, and fractionated by electrophoresis in 1% agarose 
gels. DNA was denatured and transferred to filters for 
hybridization analysis by Southern blotting (Southern, “Gel 
electrophoresis of restriction fragments, in Methods in 
Enzymology, (Wu, ed., 68, Academic Press: NY, (1979). The 
filters were hybridized with a 'PdCTP labeled human lens 
thioltransferase cDNA for 1 hr at 65° C. The membrane was 
processed as described earlier in Northern blot analysis and 
exposed to X-ray film. 
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Isolation, Purification and Cloning of Human Lens 
Thioltransferase cDNA 
Amplification of HLTT from a pool of humans lens cDNA 
by PCR resulted in a single 520 bp fragment. This fragment 
was purified and cloned into pCR 3.1 Univector and peT 
23a expression vector. The PCR fragment containing the 
entire coding Sequence for HLTT was initially cloned into 
pCR 3.1 Univector. The recombinant clone was confirmed 
for the presence and orientation of the insert by restriction 
enzyme analysis with HindIII and EcoR1 and by DNA 
Sequencing. To construct the pe.T expression System with 
HLTT, pCR 3.1-HLTT was digested with Nhe 1 and EcoR1 
to release a 540 bp fragment consisting of the entire coding 
Sequence of HLTT and the released fragment was cloned 
into Nhe 1 and EcoR1 sites of p.T 23a expression vector. 
The resulting positive clones were further confirmed for the 
presence of the insert by DNA sequencing. 
Our objectives to construct HITT clones in two different 
vectors pCR 3.1 and pET 23a were (a), to obtain large 
amounts of the enzyme by over expression in E. coli using 
the peT vector and (b), to transfect a mammalian cell line 
using the pCR 3.1 Uni Vector. Restriction enzyme analysis 
and DNA sequence analysis clearly Show that we have 
Successfully made these recombinant clones which can now 
be used for future studies. 
HLTT cDNA Sequence Analysis and Comparisons 
with Other Thioltransferases 
The nucleotide and the deduced amino acid Sequence of 
the coding region of the lens thioltransferase is shown in 
FIG. 1. The nucleotides are numbered from 5' to 3' and the 
amino acids are numbered from NH to COOH termini. The 
sequence of the PCR primers used are underlined. The 
initiator methionine and the terminator Signal are in bold. 
The 520 bp lens cDNA insert possessed a continuous open 
reading frame of 318 bp beginning with an ATG initiation 
codon and ending with a TAA termination codon followed 
by the 3'-noncoding region. The open reading frame encodes 
for a polypeptide of 106 amino acids Starting with methion 
ine and the predicted molecular weight of the encoded 
polypeptide is 11.784 KDal. On comparison with thioltrans 
ferases from other tissues using the GCG program, it was 
observed that the lens thioltransferase is 98% identical to 
that of the pig liver thioltransferase and has 87% similarity 
to that of the human placental glutaredoxin. FIG. 2 repre 
Sents the alignment of the deduced amino acid Sequence of 
lens thioltransferase to thioltransferases from other mam 
malian Systems and E. coli. Sequence A is the human lens 
thioltransferase; Sequence B is pig liver thioltransferase 
(Gan et al., “The primary structure of pig liver 
thioltransferase, J. Biol. Chem., vol.262, pp. 6699-6705 
(1987)); Sequence C is human placenta (Padilla et al., 
“Purification from placenta, amino acid Sequence, Structure 
comparisons, and cDNA cloning of glutaredoxin, Eur: J. 
Biochem., vol.227,27–34 (1995)); sequence D is calf thymus 
thioltransferase (Klintrot et al., “The primary structure of 
calf thymus glutaredoxin. Homology with the corresponding 
E. coli protein but elongation at both ends with an additional 
half-cysteine/cysteine pair, Eur: J. Biochem., vol. 144, 
pp.417-23 (1984)); sequence E is rabbit bone marrow 
(Hopper et al., “Glutaredoxin from rabbit bone marrow. 
Purification, characterization, and amino acid Sequence 
determination by tandem mass spectroscopy,” J. Biol. 
Chem., vol. 264, pp. 438-77 (1989); and sequence F is E. 
coli thioltransferase (ASlund et al., “Two additional glutare 
doxins exist in E. coli glutaredoxin is a hydrogen donor for 
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ribonucleotide reductase in a thioredoxin/glutaredoxin 1 
double mutant,” Proc. Natl. Acad. Sci. U.S.A., vol. 91, pp. 
98.13–17 (1994)). The regions indicated by “*,” “**,” and 
***** are, respectively, the active site of the enzyme, 
residues in the hydrophobic region, and the GHS binding 
site. This alignment is based on the 3D structure of E. coli 
glutaredoxin (ASlund et al., Supra) using the active site 
residues and structural elements in that molecule. AS 
expected, the human lens thioltransferase has identical 
amino acid residues in the three highly conserved regions 
which are the active site of the enzyme. GSH binding site 
and the residues in the hydrophobic region as can be seen 
from FIG. 2. Similar to placental thioltransferase human lens 
thioltransferase has a cysteine residue in position 8 replacing 
serine in other thioltransferase. The only major difference 
between the lens thioltransferase and all other thioltrans 
ferase is the presence of Valine in position 27 replacing 
arginine. 
Over Expression of HLTT in BL21 Cells 
Nhe 1 and EcoR1 fragment of pCR 3.1-HLTT was Sub 
cloned into PET 23a expression vector. Positive clones 
designated as pET 23a-HLTT were further confirmed for the 
presence and orientation of the insert by Sequence analysis. 
BL21 cells transformed with pET 23a-HLTT were then 
induced by 0.5 mM IPTG for 8 hr. There was a 65-fold 
increase in total activity of HLTT over the wild type E. coli 
after 8 hr of induction in the crude cell extract (data not 
shown). The HLTT protein band was also visualized at 11.5 
KDa on 15% SDS-PAGE with the same cell extracts after 
staining with coomassie Blue R-250 (data not shown). This 
was verified by immunoblot analysis with anti pig liver 
thioltransferase along with the pig liver thioltransferase as 
positive control which showed a gradual increase in the 
intensity of the 11.5 KDa band, thus confirming the high 
level expression of a functionally active HLTT. 
In addition, pure recombinant HLTT's intrinsic dehydro 
ascorbate reductase activity was found to be 7.8 nmoleS/ug 
thioltransferase protein when measured with dehydro ascor 
bic acid as the Substrate at 30° C. 
Radiolabeled Dethiolation Assays 
Alpha and gamma crystallin thiol mixed disulfides were 
chosen here as these are the lens proteins likely to form 
predominant disulfides with glutathione or cystine under 
oxidative StreSS and So can be considered as a well defined 
and convenient Substrate for Studying the catalysis of dis 
ulfide reduction. BSA-thiol mixed disulfides were used in 
comparison to determine the Substrate preference of lens 
thioltransferase. 
The rate of dethiolation was measured in terms of nmol of 
H-PSSG or nmol ''C-PSSC dethiolated per lug of thiol 
transferase protein. FIGS. 3A and 3B represent the time 
dependent dethiolation of PSSC and PSSC by lens thiol 
transferase. It can be seen from the slope of the reaction that 
the lens thioltransferase dethiolates gamma crystallin-GSH 
mixed disulfide more efficiently (1.15 nmol/ug 
thiol transferase), followed by alpha (0.6 nmol/ug 
thiol transferase) and BSA-GSH (0.3 nmol/ug 
thioltransferase) mixed disulfides. Due to the difference in 
the assay System these results were not compared to the 
Spectrophotometric assay which measures the loss of 
NADPH at 340 nm coupled to GSSG formation while the 
radiolabel assay measures the TCA nonprecipitable counts. 
The dethiolation of PSSC by lens thioltransferase was 
found to be lesser (50-60%) than with PSSG as can be seen 
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from the FIGS. 3A and 3B, wherein -- is control 
thioltransferase; -O- is gamma crystallin mixed disulfide; 
-O- is alpha crystallin mixed disulfide; and -A- is BSA 
mixed disulfide. FIG. 3A shows the dethiolation of alpha, 
gamma crystallins and BSA-GSH mixed disulfides (PSSG). 
FIG. 3B shows the dethiolation of alpha, gamma crystallins 
and BSA-Cystine mixed disulfides (PSSC). Interestingly, 
alpha crystalline-cystine mixed disulfide could not be dethi 
olated by lens thioltransferase Gamma crystallin-thiol mixed 
disulfide appears to be the favorable substrate for lens 
thioltransferase. 
N-terminal Amino Acid Analysis of the Human 
Lens. Thioltransferase 
The N-terminal amino acid Sequence analysis indicated 
the first 10 amino acids of the expressed enzyme to be 
AQEFVNCKIQ (amino acids 2-11 of SEQ ID NO:2) which 
is in agreement with that of the deduced amino acid 
sequence of the protein from the cDNA (FIG.1). Methionine 
which precedes alanine as deduced from the cDNA sequence 
was not found at the N terminus of the expressed recombi 
nant protein indicating its likely cleavage by the host cell. 
The expressed product, Similar to other reports, did not show 
any acetyl group at the N-termini. 
Northern Blot Analysis 
In order to determine the size of the mRNA transcript of 
lens thioltransferase, total RNA from bovine lens, pig lens, 
rabbit lens epithelial cell, pig liver, and human placenta (as 
positive control) were hybridized to the human lens thiol 
transferase cDNA labeled with P. The results showed the 
presence of a Single positive band with an approximate size 
of 0.8 kb (not shown). This also confirmed the sequence 
homology of lens thioltransferase to that of liver and pla 
cental thioltransferase. 
Southern Blot Analysis 
Genomic DNA digested with EcoR1, HindIII, Pvul, and 
SacI were examined by Southern hybridization using human 
lens thioltransferase cDNA as probe. Digestion with EcoR1 
and HindIII showed a single positive signal upon hybrid 
ization with 'P labeled human lens thioltransferase cDNA. 
SacI which has 3 restriction sites resulted in 4 fragments 
which hybridized with the HLTT cDNA while PvuII diges 
tion resulted in 2 positive signals. These results Suggest that 
the thioltransferase gene is a Single copy gene. 
The above described cloning and Sequencing of the 
human lens thioltransferase is advantageous in that we have 
been able to produce large amounts of the enzyme, which 
would not otherwise be possible due to the low concentra 
tion of the enzyme in the lens and the difficulty in obtaining 
the human lens tissue. The recombinant protein that we have 
now obtained has been characterized by SDS-PAGE, Immu 
noblots and N-terminal amino acid Sequencing and our 
results clearly demonstrate the structural similarity of HLTT 
to that of thioltransferases from other mammalian Systems. 
Southern and Northern hybridizations provide strong evi 
dence for the presence of a Single copy gene for thioltrans 
ferase and the mRNA transcript size has been found to be 
approximately 0.8 kb. 
The findings above show the dethiolation of PSSG and 
PSSC by lens thioltransferase and its intrinsic dehyrdoascor 
bate reductase activity to regenerate ascorbic acid from its 
oxidized form indicate that the antioxidant role of thioltrans 
ferase is both as a protective agent against oxidation by its 
ability to regenerate ascorbic acid and as a repair enzyme by 
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its dethiolating activity, thus preventing protein aggregation, 
an earlier event in cataractogenesis. 
The amino acid sequence of HLTT as expected was found 
to be similar to a large extent to that of other thioltrans 
ferases. This similarity involves all residues previously 
known to be highly conserved based on the 3-dimensional 
Structure of E. coli glutaredoxin or thioltransferase (ASlund 
et al., Supra), the active site with 2 half cystine residues 
cys-pro-tyr-cys (amino acids 11-14 of SEQ ID NO:7) is 
conserved in HLTT similar to other thioltransferases. In 
addition, as shown in FIG. 2, there are 2 other highly 
conserved areas outside the active Site in all the 
thioltransferases, including HLTT. These include the resi 
dues thr-Val-pro, representing the hydrophobic Surface area 
in E. coli grx and the residues ile-gly-gly-cyS-Ser (amino 
acids 80-84 of SEQ ID NOS:4 and 6) or ile-gly-gly-thr-asp 
(amino acids 69-73 of SEQID NO:7) representing the GSH 
binding site in E. coli. Another interesting observation is the 
presence of cysteine in position 8 (a non conserved region) 
and 79 (conserved region for human thioltransferases). It has 
been Speculated that these 2 residues in conjunction with the 
GSH binding site and the site of the enzyme constitute a 
redox regulatory part of the enzyme (Padilla et al., Supra). AS 
Seen in FIG. 2 showing the alignment of amino acid residues 
in thioltransferases, all thioltransferases exhibit a high 
degree of Similarity, indicating a highly conserved Structure. 
The human lens thioltransferase on the whole has 5 cysteine 
residues similar to human placental thioltransferase, an 
internal methionine and histidine in contrast to human 
placental thioltransferase, which does not have these resi 
dues and there are no tryptophan residues as reported by 
Mieyalet al., Biochemistry, vol. 30, 6088-97 (1991), in the 
RBC thioltransferase. Cystine 8 is a replacement of serine in 
human lens thioltransferase similar to te report of Padilla et 
al., Supra, on human placental thioltransferase. Another 
interesting observation is the replacement of arginine with 
valine in HITT in position 27 immediately following the 
active Site. 
Also contemplated as within the Scope of the present 
invention is the use of an HLTT clone such as the pCR3.1- 
HLTT clone as described herein transfect mammalian cell 
lines, and the cell lines So transfected. Such transfected cell 
lines are useful in that they can be used to evaluate the effect 
of thioltransferase on lens proteins Subjected to oxidative 
StreSS. Also contemplated as within the Scope of the inven 
tion are antisense polynucleotides and a method for causing 
thioltransferase depletion in a cell by the introduction of an 
antisense molecule. Such an antisense molecule may be an 
RNA or a single stranded DNA that is complimentary to the 
mRNA of the HLTTgene to prevent translation of the HLTT 
protein. Such antisense molecules are useful evaluating the 
effect of thioltransferase depletion. The creation and com 
parison of cell lines which over and under express thiol 
transferase would also be useful in providing an excellent 
model for the study of the cellular functions of oxidative 
StreSS in general, and cataractogenesis in particular. 
The following Examples demonstrate that, under oxida 
tive StreSS induced by H2O exposure, thioltransferase 
shows remarkable resistance to oxidation, while other 
defense enzymes, Such as glutathione peroxidase and glu 
tathione reductase, exhibit a transient loSS of activity. 
Materials 
Rabbit lens epithelial cell lines, N/N 1003 A and OB3L 
were established in Dr. John Reddan's laboratory at Oakland 
University, Rochester, Mich. MEM, rabbit serum, trypsin 
15 
25 
35 
40 
45 
50 
55 
60 
65 
20 
EDTA (1X) and gentamicin Solution, glutathione, glu 
tathione reductase, glutathione Sulfonic acid, cysteic acid 
and H2O, were from Sigma Chemical Company (St. Louis, 
Mo.). Hydroxyethyl disulfide (HEDS) was purchased from 
Aldrich Chemical Company (Milwaukee, Wis.). The BCA 
protein assay kit was from Pierce Chemical Company 
(Rockford, Ill.). Nylon membrane and nitrocellulose mem 
brane were from Schleicher and Schuell (Keene, N.H.). 
Ethidium bromide was purchased from Boehringer Man 
nheim Corp. (Indianapolis, Ind.). All other chemicals and 
reagents were of analytical grade. 
Rabbit Lens Epithelial Cell Culture 
Rabbit lens epithelial cell line N/N1003 A was developed 
from a four-day-old rabbit (Reddan et al., “Establishment of 
epithelial cell lines from individual rabbit lenses,” J. Tissue 
Culture Methods, vol. 6, 57–60 (1980); Reddan et al., 
"Retention of lens Specificity in long-term cultures of dip 
loid rabbit lens epithelial cells,” Differentiation, vol.33, 
168-174 (1986)) and OB3L was from an eight-year-old 
rabbit ( Reddan et al., “Establishment and characterization 
of a lens epithelial cell line from an 8-year old rabbit,” Curr. 
Eye Res., vol. 2,633–639 (1983)). Cells were grown in 5 ml 
of MEM with 50 tug/ml gentamicin plus 8% rabbit serum 
(pH 7.2) in 60x15 mm tissue culture plates in a humidified 
atmosphere with 5% CO at 35.5° C. Cells reached 95% 
confluence (-2x10 cells) within 3–4 days. They were 
divided four to one with fresh medium and Subcultured. 
HO. Treatment of Lens Epithelial Cells in Culture 
Rabbit lens epithelial cells were raised to confluence, 
trypsinized and plated at 0.8 million in each dish. The cells 
were incubated overnight in MEM with 1% rabbit serum and 
then in Serum free MEM for 30 min before a bolus of 0.5 
mM HO was added. Serum-free medium was used to 
minimize reaction of peroxide with Serum proteins. At 
intervals of 5, 15, 30 min and up to 3 hours, cells in 
quadruplicate plates were harvested and used for various 
enzymatic assays (TTase, GR, GPX and G-3PD). Free GSH, 
total SH and protein-thiol mixed disulfides (PSSG and 
PSSC) were determined. HO in the medium was measured 
at each time point. A portion of the cells was Saved for a 
DNA fragmentation assay. Other cells were photographed 
and tested for viability by Trypan Blue staining. Cells were 
also exposed to different levels of H2O (0.5-1.0 mM) to 
Study the resistance of thioltransferase to HO stress. In 
each Study, cells incubated without HO were used as 
controls. 
Harvest of Cells and Preparation of Cell 
Homogenate 
The cells in each plate were harvested by Scraping with a 
rubber policeman and the Suspension was centrifuged at 
1,700xg for 15 min at 4 C. The pellet was resuspended in 
5 ml, 2 mM EDTA, Sonicated to break the cells and 
centrifuged to collect the Supernatant, which was either used 
immediately or stored at -20° C. for biochemical assays. 
Protein content in the homogenate was determined using a 
Pierce BCA kit, following the method of Smith et al., 
“Measurement of protein using BCA.” Anal. Biochem., 
vol. 150, 76–85 (1985). 
Quantification of Total Thiols, GSH and Protein 
Thiol Mixed Disulfides 
A portion of the cell homogenate was centrifuged and the 
Supernatant was immediately used for total thiol assay (GSH 
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plus Protein thiol) following the method of Ellman, “A 
colorimetric method for determining low concentrations of 
mercaptains,” Arch. Biochem. BiophyS., vol.74, 443-50 
(1958). Another portion of the homogenate was treated with 
an equal volume of 20% TCA, centrifuged and the Super 
natant was immediately assayed for GSH with Ellman's 
reagent (expressed as nmoles/mg protein). The TCA pre 
cipitate was used for quantification of PSSG and PSSC 
following the method of Lou et al., “Protein-thiol mixed 
disulfides in human lens,” Exp. Eye Res., 55,889–96 (1992). 
Briefly, the TCA precipitate was washed thoroughly (3x) 
with 10% TCA followed by a wash with ether/methanol (1/1, V/v) and dried in a dry heating bath (65 C.) overnight. 
The dried protein was pulverized and then oxidized with 
performic acid to release non-protein thiols from lens pro 
teins. The released products of GSH (as glutathione sulfonic 
acid), and cysteine (as cysteic acid) were quantified by anion 
eXchange amino acid analysis using a DioneX LC System 
(Sunnyvale, Calif.). Values were expressed as nmoles/mg 
dry weight. 
Enzyme ASSays of the Cell Homogenate 
In each enzyme assay, reaction mixtures without the cell 
homogenate were used as blanks. The activity of each 
enzyme was expressed as miniumit (mu)/mg protein. Thiol 
transferase was assayed following the method of Mieyal et 
al., Supra, as modified by Raghavachari et al., “Evidence for 
the presence of thioltransferase in the lens,” Exp. Eye Res., 
vol. 63, 433-41 (1996). The reaction was carried out in the 
presence of NADPH, GSH and GR with the synthetic 
disulfide, hydroxyethyl disulfide (HEDS), as substrate. The 
decreased O.D., for NADPH was monitored for enzyme 
activity. GPx was assayed following the method described 
by Spector et al., “The prevention of cataract caused by 
oxidative stress in cultured rat lenses. I.H2O and photo 
chemically induced cataract,” Curr. Eye ReS., Vol.12, 
163-179 (1993), based on the decreased absorption at 366 
nm as the result of GPx catalyzed oxidation of NADPH by 
substrate H.O. GSH and GR were added as cofactors. The 
GR assay was performed following the method of Straatsma 
et al., "Lens capsule and epithelium in age-related cataract,” 
Am. J. Ophthalmol., vol. 112,283-96(1991), using GSSG as 
substrate. The decreased absorbance (340 nm) with NADPH 
consumption was monitored for GR activity. G-3PD activity 
was determined using the method of Byers, 
“Glyceraldehyde-3-phosphate dehydrogenase from yeast,” 
Methods Enzymol., vol.89, 327–35 (1982), modified by 
Spector et al. (1993), Supra. The reaction was initiated by 
addition of glyceraldehyde-3-phosphate and the change in 
absorbance at 340 nm between 20-50 second was used to 
determine G-3PD activity. 
H.O. Measurement in the Culture Medium 
The concentration of H2O, was measured using a colo 
rimetric method of Hildebrandt et al., “Hydrogen peroxide 
in hepatic microsomes,” Meth. Enzymol, vol. LII, 342-350 
(1978), modified by Spector et al. (1993), supra. An aliquot 
of the medium (50 uL) was mixed thoroughly with 950 uL 
of autoclaved, double-distilled water containing 50 till of 
50% TCA, followed by mixing with 50 uL of 30 mM 
ferroammonium sulfate and 50 uL of 2.5 M KSCN. The 
absorbance was read at 480 nm after Standing at room 
temperature for 10-15 min. A standard curve of HO, with 
known concentrations was generated for calculation. 
Assay for DNA Fragmentations in the Epithelial 
Cells 
DNA fragmentation analyses followed the procedures of 
Hogquist et al., “Interleukin which is processed and released 
22 
during apoptosis,” Proc. Natl. Acad. Sci. U.S.A., vol. 88, 
8485-8490 (1991), and Prigent et al., “A safe and rapid 
method for analysing apoptosis-induced fragmentation of 
DNA extracted from tissues or cultured cells,” J. Immunol. 
5 Methods, vol. 160, 139-140 (1993). This method is used to 
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analyze apoptosis-induced fragmentation of DNA. Approxi 
mately 5x10 cells were washed in serum-free medium and 
centrifuged to collect the cell pellet. DNA was then isolated 
and treated with RNase to remove RNAbefore separating by 
agarose gel electrophoresis (2%). DNA was stained by 
ethidium bromide and photographed under UV illumination. 
Effect of HO on the Growth of Lens Epithelial 
Cells 
Three rabbit epithelial cell lines N/N 1003A and OB3L 
were each seeded at 5x10" per plate containing 5 ml MEM 
plus 1% rabbit serum. Cells cultured in MEM with 1% rabbit 
Serum remain viable but do not grow. Three plates from each 
line were counted 20 hours later to Verify the Starting count. 
Cells from the remaining plates were cultured for 30 minutes 
in Serum-free MEM and then in medium containing a single 
dose of 0.05 mM HO. After 3 hrs, the medium was 
replaced with MEM containing 8% rabbit serum. The 
Serum-containing medium was replaced on days three and 
Six and cells were counted on day Seven using a Coulter 
Counter (Miami, Fla.). 
Effect of a Single Bolus of HO on Lens Cells 
A single dose of H2O (0.5 mM) in the medium was 
degraded quite rapidly when incubated in the presence of 
800,000 lens epithelial cells. FIG. 4 depicts the detoxifica 
tion of bolus HO (0.5 mM) by rabbit lens epithelial cell 
line N/N1003A in the absence of lens cells (-O-) and in the 
presence of lens cells (--). The level of HO in the 
medium decreased with time. Half of the HO was detoxi 
fied after 30 min and it was completely dissipated within 120 
min. In contrast, the level of HO remained constant when 
added to MEM and incubated without cells. The morphol 
ogy of the H-O-treated N/N1003A cells was identical to 
controls during the 3 hr exposure. Trypan Blue Staining 
confirmed that the cells exhibited little or no cell death (data 
not shown). DNA fragmentation assay (data not shown) 
showed that these cells exhibited no DNA damage, strongly 
confirming the absence of apoptosis. 
Effect of Bolus HO. Treatment on Lens SH and 
Protein-Thiol Mixed Disulfides 
Following treatment with 0.5 mM HO the cellular GSH 
level dropped 60% from 68.7+14.9 nmoles/mg protein 
within five min and stayed at this level before it began to 
increase at 90 min and recovered to nearly 100% of normal 
by two hrs (FIG. 5). FIG. 5 shows the effect of bolus HO 
to lens GSH and protein-thiol mixed disulfide in N/N 1003A 
cells wherein GSH level is represented by -O-, PSSG level, 
measured as GSO3H, is represented by --, PSSC level, 
measured as CSO3H, is represented by -O-. The initial GSH 
concentration was 68.7+14.9 nmoles/mg; PSSG was 
0.19+0.02 nmoles/mg dry wt (n=4); PSSC was 0.07+0.01 
nmoles/mg dry wt. The total SH groups (GSH plus protein 
SH) showed a similar pattern to free GSH in response to 
HO (data not shown). In contrast to the decrease in GSH, 
protein-thiol mixed disulfides were greatly increased. AS 
shown in FIG. 5, PSSG was elevated 6.5 fold over the basal 
level of 0.07+0.01 nmoles/mg dry wt and reached a plateau 
within 15 minutes. The increase in protein-thiol mixed 
disulfides was inversely related to the level of GSH in the 
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cells. The level of protein-thiol mixed disulfides began to 
decline only after the level of free GSH increased. At this 
time H2O in the medium was almost completely detoxified 
(90 min). The PSSG level continued to decrease at intervals 
beyond 60 min (see FIG. 5). Similar to PSSG but in much 5 
Smaller scale, the level of PSSC also peaked (2-fold increase 
from a basal level of 0.19+0.02 nmoles/mg dry wt) 30 min 
after HO was added and then decreased to the basal level 
at 90 min. 
1O 
Effect of a Bolus of HO on Enzymes in Lens 
Epithelial Cells 
Since this study is focused on the response of thioltrans 
ferase to H2O, it was considered important to compare the 
effect of HO on the activity of thioltransferase with its 
effect on other enzymes. FIG. 6 shows the effect of bolus 
HO (0.5 mM) on enzyme activities in N/N1003A cells 
wherein -O- represents thioltransferase; -O- represents 
glycero-3-phosphate dehydrogenase; -- represents glu 
tathione peroxidase; and -O- represents glutathione reduc 
tase. The initial thioltransferase activity was 16.0+5.6 
mU/mg (n=24); G-3PD was 167+5.5 mU/mg (n=4); GPx 
was 19.1+4.3 mu/mg (n=4); GR was 26.4+1.8 mU/mg (n8). 
The data is expressed as mean+S.D. As shown in FIG. 6, 
glycero-3-phosphate dehydrogenase (G-3PD) was the most 
sensitive to H2O of the enzymes tested. It lost 95% of its 
activity from the initial value of 167+5.5 m U/mg within 5 
min of H2O treatment. The activity was regained quickly 
when HO began to diminish in the medium. When 
HO was no longer present in the medium (120 min), 
G-3PD regained 40% of its activity and recovered up to 60% 
of the activity after 180 min. A less severe and delayed 
inhibition was observed in the activity of both GPx (60% 
maxima loss at 60 min from 19.1+4.3 mU/mg) and GR (30% 
maxima loss at 90 min from 26.4+1.8 mU/mg). In marked 
contrast, thioltransferase activity remained constant during 
the entire experiment (at 16+5.6 mU/mg, see FIG. 6). Only 
when a higher dose of H2O (0.8-1.0 mM) was used, did 
thioltransferase show a brief loss in activity (<30% maxi 
mum at 60 min) and a Swift recovery (FIG. 7). FIG. 7 shows 
thioltransferase activity in lens epithelial cells (N/N 1003A) 
treated with various HO levels wherein -A- represents 0.5 
mM HO2; -O- represents 0.8 mM H.O.; and -O- repre 
sents 1.0 mM HO. The initial thioltransferase activity was 
16.0+5.6 mU/mg (n=24). 
One other line of rabbit lens epithelial cells was tested for 
its response to HO. OB3L, which originated from an 
eight-year old rabbit, showed Similar pattern in 
thioltransferase, GSH and G-3PD activity as line N/N1003A 
(FIG. 6) after HO treatment (data not shown). 
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Effect of HO on the Growth of Rabbit Lens 
Epithelial Cells 
Since proliferation is a sensitive indicator of oxidative 55 
damage we examined the effect of a single dose of 0.05 mM 
HO on the growth of 50,000 cells from each of the cell 
lines. Controls were not treated with H.O. Cells (50,000) in 
serum-free MEM were exposed to 0.05 mM HO. Three 
hours after HO addition, cells were cultured in MEM 
containing 8% rabbit Serum, a medium known to foster cell 
proliferation. Cells were counted 7 days after HO treat 
ment. The cells that were not exposed to H2O, increased to 
2-2.5 million cells in seven days. The susceptibility of the 
two cell lines to HO-induced growth inhibition varied. 65 
Cell line N/N 1003A was more resistant to oxidation and 
grew from 50,000 to 830,000 cells, a 16-fold increase over 
60 
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the inoculum. Cells from line OB3L increased to 180,000, a 
3.6 fold increase in number. These results are Summarized in 
FIG.8 wherein Orepresents the starting count, O represents 
the control, and X represents the HO treated cells. 
Rabbit lens epithelial cell line N/N1003A was chosen 
Since it has a high level of antioxidant enzymes (Giblin et al., 
“Detoxification of HO, by cultured rabbit lens epithelial 
cells: Participation of the glutathione redox cycle, Exp. Eye 
Res., vol. 40, 827–40 (1985); Giblin et al., “The relative 
roles of the glutathione redox cycle and catalase in the 
detoxification of HO, by cultured rabbit lens epithelial 
cells,” Exp. Eye Res., vol. 50,795–804 (1990)). This study 
focused on thioltransferase, an enzyme that has not been 
previously studied in cultured lens epithelial cells. The 
protocol for the present Study of oxidative-StreSS induced by 
a bolus of HO was similar to that of Giblin et al., 1990, 
Supra. The rate of H2O2 dissipation in this study agrees with 
the earlier report (Giblin et al., 1990, Supra). HO in the 
medium was removed very efficiently by the lens cells from 
the two rabbit cell lines, indicating that these cells can 
defend themselves against this level of oxidative insult. 
Cells from line N/N1003A subjected to a bolus of HO 
exhibited a normal morphology without visible DNA frag 
mentation. The fact that there was no DNA fragmentation is 
consistent with the viability and growth data and indicates 
that the cells exposed to H2O2 did not undergo apoptosis. It 
should be noted however, that HO does induce Single 
strand breaks in DNA following exposure of lens epithelial 
cells to H2O (Spector et al., “Repair of H-O-induced DNA 
damage in bovine lens epithelial cell cultures,” Exp. Eye 
Res., vol. 49,685-698 (1989); Reddan et al., “The superox 
ide dismutase mimic TEMPOL protects cultured rabbit lens 
epithelial cells from hydrogen peroxide insult, Exp. Eye 
Res., vol.56,543–554 (1993)). N/N1003A showed a stronger 
resistance to HO induced mitotic inhibition (see FIG. 8) 
compared to cells from the other cell line, OB3L. One of the 
factors that may contribute to the increased Susceptibility of 
line OB3L to H2O insult is that these cells have a lower 
level of GR than line N/N1003A (Reddan et al., “Influence 
of the activity of glutathione reductase on the response of 
cultured lens epithelial cells from young and old rabbits to 
hydrogen peroxide,” Exp. Eye Res., vol. 45, 209-221 
(1988)). 
The redox status of the cells changed with the amount of 
HO present in the medium. At the initial burst of oxidation, 
GSH immediately decreased, likely due to its Swift usage for 
various defense enzymes to combat the StreSS. The oxidized 
GSH quickly formed protein-GSH mixed disulfide, as can 
be seen in FIG. 5 where a mirror image of these two 
parameters is shown. The total thiols in the cells also 
decreased during this period, reflecting the general change in 
the redox Status, i.e., Sulfhydryl groups in GSH and proteins 
were oxidized with the concomitant formation of protein 
thiol mixed disulfides. GSH levels began to recover as HO 
in the medium diminished. Moreover, as the intracellular 
level of GSH increased, the accumulated PSSG in the cell 
decreased. This finding agrees with the lens organ culture 
studies where elevated PSSG was spontaneously dethiolated 
over a period of time after the H2O exposed lens was 
cultured in peroxide-free medium (Cuiet al., “The effect and 
recovery of long term HO exposure on lens morphology 
and biochemistry.” Exp. Eye. Res., vol. 57, 157-167 (1993); 
Lou et al., “Recovery of oxidative damage in human lenses,” 
Invest. Ophthalmol. Vis. Sci. vol. 35 (Suppl.), 1569 (1994); 
Lou et al., “Further Studies on the dynamic changes of 
glutathione and protein-thiol mixed disulfides in H2O2 
induced cataract in rat lenses: distributions and effect of 
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aging, Curr. Eye Res., vol. 14.951-958 (1995); Wang et al., 
“Relationship of protein-glutathione mixed disulfide and 
thioltransferase in H-O-induced cataract in cultured pig 
lens,” Exp Eye Res., vol. 64, 693–700 (1997)). In the organ 
culture Study, we speculated that an enzyme must be present 
in the lens to dethiolate the glutathione thiolated protein 
(PSSG). This may also apply to the lens epithelial cells. Our 
recent discovery of the dethiolating enzyme, 
thioltransferase, in the lens and the presence of mRNA in the 
cultured lens epithelial cells (Wu et al., Distribution of 
thioltransferase in ocular tissues.” Invest. Ophthalmol. Vis. 
Sci., vol. 39, 476-80 (1998)) strongly supports such a 
hypothesis. 
Of all the enzymes tested in this study thioltransferase 
was the only one whose activity was not adversely affected 
by H2O2. This oxidative StreSS-resistant nature was uniform 
in both rabbit lens cell lines. Thioltransferase activity was 
only slightly reduced when cells from line N/N1003A were 
exposed to a bolus of 0.8-1.0 mM H.O. (FIG. 7). G-3PD 
was extremely Sensitive to oxidation, which agrees with the 
observation of Jedziniak, “Photo-oxidative damage to len 
ticular GAPDH and its relationship to aldehyde 
metabolism.” Exp. Eye Res., vol. 50, 589–596 (1990). The 
phenomenon of a near-total loSS in activity at the onset of 
H2O insult and a slow recovery in activity of this enzyme 
was noted in the present Study. Two known oxidation 
defense enzymes, GR and GPX showed a substantial loss of 
activity before they were restored. 
Axelsson et al., “An essential role of cytosolic thioltrans 
ferase in protection of pyruvate kinase form rabbit liver 
against oxidative inactivation,” FEBS Lett., vol., 152, 
114-118 (1983), reported the protective role of thioltrans 
ferase against an inactivated pyruvate kinase by oxidative 
stress in rabbit liver. G-3PD, a thiol-dependent enzyme may 
also preserve its activity against oxidation by thioltrans 
ferase and GSH in human lung carcinoma cells (Brodie et 
al., “Cellular recovery of glyceraldehyde-3-phosphate dehy 
drogenase activity and thiol Status after exposure to 
hydroperoxides,” Arch. Biochem. BiophyS., vol. 276, 
212-218 (1990)). The high oxidation-resistant nature of 
thioltransferase, coupled with its Suggested mechanism of 
action (Terada et al., “Study on human erythrocyte thiol 
transferase: Comparative characterization with bovine 
enzyme and its physiological role under oxidative StreSS, J. 
Biochem., vol. 111, 688–692 (1992); Starke et al., “Sensi 
tivity of protein Sulfhydryl repair enzymes to oxidative 
stress,” Free Radical. Biol. S. Med., vol. 23, 373-384 
(1997)) makes it a candidate responsible for repairing the 
damage induced by oxidative StreSS. AS Shown above, lens 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 9 
<210> SEQ ID NO 1 
&2 11s LENGTH 522 
&212> TYPE DNA 
<213> ORGANISM: Homo sapiens 
&22O > FEATURE 
<221 NAME/KEY: CDS 
<222> LOCATION: (4) . . (324.) 
<400 SEQUENCE: 1 
gcc atg gct caa gag titt gtgaac toc aaa atc cag cot gog aag gtg 
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thioltransferase can dethiolate PSSG and PSSC (more pref 
erence to PSSG), similar to thioltransferase in red blood 
cells (Gravina et al., “Thioltransferase is a specific glutathio 
nyl mixed disulfide oxidoreductase,” Biochemistry, vol. 32, 
3368–3376 (1993)). It is likely that the defense enzymes 
such as GR, GPx and the energy providing enzyme G-3PD 
in the cells were all thiolated and inactivated (through SH 
groups in these enzymes) under the oxidative-stress induced 
by HO. Thioltransferase, being resistant to oxidation, with 
the help of adequate levels of cellular GSH and GR, may 
thus function as a rescuer by dethiolating the inactivated 
enzymes and restoring their activity. The following Example 
was performed to determine the role of thioltransferase in 
restoring G3PD activity after oxidative stress. 
Regeneration of G3PD from Rabbit Epithelium 
Cell Culture after Oxidative Stress 
1.6 million of rabbit epithelium cells were exposed to 0.5 
mM HO for 15 minutes. The cells were resuspensed in 2 
ml of EDTA pH 8.0 and broken by Sonication. After 
centrifugation, the Supernatant was desalted with PD-10 
column which equilibrated and eluted with 2 mM EDTA. 
The elute with G3PD was collected and concentrated with 
centriprep 3 into about 1 ml for the following regeneration. 
100 till of the above sample was incubated with 0.3 mM 
NADPH, 1 mM GSH, (stock solutions 2 mM NADPH in 50 
mM triethanolamine, pH 7.5 and 5 mM GSH in 50 mM 
triethanolamine, ph 7.5), 3 U GR/ml and about 0.3 U of 
recombinant human lens thioltransferase (RHLT) in a total 
volume of 0.2 ml at 25° C. for 0–60 min. G3PD activity 
regenerated by GSH recycling system with and without 
thioltransferase was represented as the percentage of G3PD 
activity regenerated by 30 mM DTT. The results are shown 
in FIG. 9. The time dependency of regeneration of G3PD 
from H2O (0.5 mM) pretreated rabbit cell by purified 
recombinant human lens thioltransferase is shown in FIG. 
10. 
The description above should not be construed as limiting 
the Scope of the invention, but as merely providing illustra 
tions to some of the presently preferred embodiments of this 
invention. In light of the above description and examples, 
various other modifications and variations will now become 
apparent to those skilled in the art without departing from 
the Spirit and Scope of the present invention as defined by the 
appended claims. Accordingly, the Scope of the invention 
should be determined Solely by the appended claims and 
their legal equivalents. All references cited herein are hereby 
incorporated by reference in their entireties. 
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-continued 
Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val 
1 5 10 15 
gta gtt titc atc aag ccc acc toc coc titc toc gta aag aca cag gag 96 
Val Val Phe Ile Lys Pro Thr Cys Pro Phe Cys Val Lys Thr Glin Glu 
2O 25 30 
citc ctic agc caa ttg ccc titc aaa gaa ggg citt citg gaa titt gtc gat 144 
Leu Lleu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lleu Glu Phe Val Asp 
35 40 45 
att aca gcc acc agt gac acc aac gag att caa gat tat citg caa cag 192 
Ile Thr Ala Thr Ser Asp Thr Asn Glu Ile Glin Asp Tyr Leu Gln Glin 
5 O 55 60 
citc aca gga gCC aga acg gta colt c.gg gtc titt atc ggit aaa gag tot 240 
Leu Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys 
65 70 75 
ata ggt gga toc act gat cita gala agt at g cac aag aga ggg gag citc 288 
Ile Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu 
8O 85 90 95 
ttg acc cgc citg cag caa att gga gct citg aaa taa ttacagcaga 334 
Lieu. Thir Arg Lieu Glin Glin Ile Gly Ala Lieu Lys 
1 OO 105 
gcag accolaa gotgatagot coctitgagag citggatggca gtgcagataa togacagogct 394 
to citggtgga tiggatgcc.gg gctacct tca citcagotgca act actottt acttaaaaat 454 
totgaaatgt gttaa.cccaa ataattgggg ggagtgg gtt ttgggggaca aaacagattit 514 
ttcttctg 522 
<210> SEQ ID NO 2 
&211's LENGTH 106 
&212> TYPE PRT 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 2 
Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val Val 
1 5 10 15 
Val Phe Ile Llys Pro Thr Cys Pro Phe Cys Val Lys Thr Glin Glu Leu 
2O 25 30 
Leu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lieu Glu Phe Wall Asp Ile 
35 40 45 
Thr Ala Thir Ser Asp Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu 
5 O 55 60 
Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys Ile 
65 70 75 8O 
Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu Lieu 
85 90 95 
Thr Arg Lieu Glin Glin Ile Gly Ala Lieu Lys 
100 105 
<210> SEQ ID NO 3 
&2 11s LENGTH 106 
&212> TYPE PRT 
<213> ORGANISM: Sus scrofa 
<400 SEQUENCE: 3 
Met Ala Glin Ala Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val 
1 5 10 15 
Val Phe Ile Llys Pro Thr Cys Pro Phe Cys Arg Lys Thr Glin Glu Leu 
2O 25 30 
Leu Ser Glin Leu Pro Phe Lys Glu Gly Lieu Lieu Glu Phe Wall Asp Ile 
28 
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-continued 
35 40 45 
Thr Ala Thir Ser Asp Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu 
5 O 55 60 
Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Glu Cys Ile 
65 70 75 8O 
Gly Gly Cys Thr Asp Leu Glu Ser Met His Lys Arg Gly Glu Lieu Lieu 
85 90 95 
Thr Arg Lieu Glin Glin Ile Gly Ala Lieu Lys 
100 105 
<210> SEQ ID NO 4 
&2 11s LENGTH 106 
&212> TYPE PRT 
<213> ORGANISM: Homo sapiens 
<400 SEQUENCE: 4 
Met Ala Glin Glu Phe Val Asn Cys Lys Ile Gln Pro Gly Lys Val Val 
1 5 10 15 
Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Arg Ala Glin Glu Ile 
2O 25 30 
Leu Ser Glin Leu Pro Ile Lys Glin Gly Lieu Lieu Glu Phe Wall Asp Ile 
35 40 45 
Thr Ala Thr Asn His Thr Asn. Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu 
5 O 55 60 
Thr Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Lys Asp Cys Ile 
65 70 75 8O 
Gly Gly Cys Ser Asp Leu Val Ser Leu Glin Gln Ser Gly Glu Leu Leu 
85 90 95 
Thr Arg Lieu Lys Glin Ile Gly Ala Leu Glin 
100 105 
<210 SEQ ID NO 5 
&2 11s LENGTH 105 
&212> TYPE PRT 
<213> ORGANISM Bos taurus 
<400 SEQUENCE: 5 
Met Ala Glin Ala Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val 
1 5 10 15 
Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Lys Thr Glin Glu Leu 
2O 25 30 
Leu Ser Glin Leu Pro Phe Lys Glin Leu Lieu Glu Phe Val Asp Ile Thr 
35 40 45 
Ala Ala Gly Asn. Ile Ser Glu Ile Glin Asp Tyr Lieu Glin Glin Lieu. Thr 
5 O 55 60 
Gly Ala Arg Thr Val Pro Arg Val Phe Ile Gly Glin Glu Cys Ile Gly 
65 70 75 8O 
Gly Cys Thr Asp Leu Val Asn Met His Glu Arg Gly Glu Lieu Lieu. Thr 
85 90 95 
Arg Lieu Lys Glin Met Gly Ala Leu Glin 
100 105 
<210> SEQ ID NO 6 
&2 11s LENGTH 107 
&212> TYPE PRT 
<213> ORGANISM: Oryctolagus cuniculus 
<400 SEQUENCE: 6 
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Met Ala Glin Glu Phe Val Asn Ser Lys Ile Gln Pro Gly Lys Val Val 
1 5 10 15 
Val Phe Ile Llys Pro Thr Cys Pro Tyr Cys Arg Lys Thr Glin Glu Ile 
2O 25 30 
Leu Ser Glin Leu Pro Phe Lys Glin Gly Lieu Lieu Glu Phe Wall Asp Ile 
35 40 45 
Thr Ala Thr Ser Asp Met Ser Glu Ile Glin Asp Tyr Leu Gln Glin Leu 
5 O 55 60 
Thr Gly Ala Arg Thr Val Pro Arg Val Phe Leu Gly Lys Asp Cys Ile 
65 70 75 8O 
Gly Gly Cys Ser Asp Lieu. Ile Ala Met Glin Glu Lys Gly Glu Lieu Lieu 
85 90 95 
Ala Arg Lieu Lys Glu Met Gly Ala Lieu Arg Glin 
100 105 
<210 SEQ ID NO 7 
&2 11s LENGTH 85 
&212> TYPE PRT 
<213> ORGANISM: Escherichia coli 
<400 SEQUENCE: 7 
Met Glin Thr Val Ile Phe Gly Arg Ser Gly Cys Pro Tyr Cys Val Arg 
1 5 10 15 
Ala Lys Asp Leu Ala Glu Lys Lieu Ser Asn. Glu Arg Asp Asp Phe Glin 
2O 25 30 
Tyr Glin Tyr Val Asp Ile Arg Ala Glu Gly Ile Thr Lys Glu Asp Lieu 
35 40 45 
Gln Glin Lys Ala Gly Lys Pro Val Glu Thr Val Pro Glin Ile Phe Val 
5 O 55 60 
Asp Glin Gln His Ile Gly Gly Tyr Thr Asp Phe Ala Ala Trp Wall Lys 
65 70 75 8O 
Glu Asn Lieu. Asp Ala 
85 
<210 SEQ ID NO 8 
<211& LENGTH 21 
&212> TYPE DNA 
<213> ORGANISM: Sus scrofa 
<400 SEQUENCE: 8 
agcatggctc. aag catttgt g 
SEQ ID NO 9 
LENGTH 24 
TYPE DNA 
ORGANISM: Sus scrofa 
<400 SEQUENCE: 9 
gaagaaaaat citgttttgtc. ccc.c 
21 
24 
What is claimed is: 
1. A method of inhibiting the formation of a cataract in an 
eye, which comprises contacting the eye with an effective 
cataract-inhibiting amount of a human lens thioltransferase 
(HLTT). 
2. The method according to claim 1, wherein Said human 
lens thioltransferase is an expression product of a trans 
formed host cell comprising a DNA molecule coding for 
HLTT. 
60 
65 
3. The method according to claim 1, wherein the eye 
contains a developing or fully developed cataract. 
4. The method according to claim 1, wherein the eye does 
not contain a developing or fully developed cataract. 
5. A method of inhibiting the formation of a cataract in an 
eye, which comprises administering to the Subject a phar 
maceutical composition which comprises an effective 
cataract-inhibiting amount of a human lens thioltransferase. 
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6. The method according to claim 5, wherein said human 
lens thioltransferase is an expression product of a trans 
formed host cell comprising a DNA molecule coding for 
HLTT. 
7. The method according to claim 5, wherein the eye 
contains a developing or fully developed cataract. 
8. The method according to claim 5, wherein the eye does 
not contain a developing or fully developed cataract. 
9. The method according to claim 5, wherein the subject 
is a mammal. 
10. The method according to claim 9, wherein the subject 
is a human. 
11. The method according to claim 5, wherein adminis 
tering the pharmaceutical composition to the Subject com 
prises applying the pharmaceutical composition to the eye of 
the Subject. 
12. A method of inhibiting the progression of cataract 
formation in an eye of a Subject which comprises adminis 
tering to the Subject a pharmaceutical composition which 
comprises an effective cataract-inhibiting amount of a 
human lens thioltransferase. 
13. The method according to claim 12, wherein said 
human lens thioltransferase is an expression product of a 
transformed host cell comprising a DNA molecule coding 
for HLTT. 
14. The method according to claim 12, wherein the eye 
contains a developing or fully developed cataract. 
15. The method according to claim 12, wherein the eye 
does not contain a developing or fully developed cataract. 
16. A method of inhibiting the progression of cataract 
formation in an eye which comprises contacting the eye with 
an effective cataract-inhibiting amount of a human lens 
thioltransferase. 
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17. The method according to claim 16, wherein said 
human lens thioltransferase is an expression product of a 
transformed host cell comprising a DNA molecule coding 
for HLTT. 
18. The method according to claim 16, wherein the eye 
contains a developing or fully developed cataract. 
19. The method according to claim 16, wherein the eye 
does not contain a developing or fully developed cataract. 
20. The method according to claim 12, wherein admin 
istering the pharmaceutical composition to the Subject com 
prises applying the pharmaceutical composition to the eye of 
the Subject. 
21. A method of delaying the onset of cataract formation 
in an eye of a Subject which comprises administering to the 
Subject a pharmaceutical composition which comprises an 
effective cataract-inhibiting amount of a human lens thiol 
transferase. 
22. The method according to claim 21, wherein Said 
human lens thioltransferase is an expression product of a 
transformed host cell comprising a DNA molecule coding 
for HLTT. 
23. A method of treating a cataract in an eye of a Subject 
which comprises administering to the Subject a pharmaceu 
tical composition which comprises an effective cataract 
inhibiting amount of a human lens thioltransferase. 
24. The method according to claim 23, wherein said 
human lens thioltransferase is an expression product of a 
transformed host cell comprising a DNA molecule coding 
for HLTT. 
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